Table 4.

Treatment in acute myocarditis due to COVID-19 and prognosis

	Case 1 [13]	Case 2 [14]	Case 3 [15]	Case 4 [16]	Case 5 [17]	Case 6 [18]	Case 7 [19]	Case 8 [20]	Case 9 [21]	Case 10 [22]
Corticosteroids	No	Yes	N/A	Yes	Yes	Yes	N/A	Yes	Yes	No
Interferon/lopinavir/ritonavir	No/no	Yes/yes	N/A	No/yes	No/no	Yes/yes	N/A	No/no	No/no	No
NSAIDS/colchicine	No/no	No	N/A	No/no	No/yes	No/no	N/A	No/no	No/no	No
Immunoglobulin	N/A	Yes	N/A	No	No	Yes	N/A	Yes	No	No
β-blocker	Yes	No	N/A	Yes	No	No	N/A	No	No	No
ACE-inhibitor	Yes	No	N/A	No	No	No	N/A	No	No	No
Inotropes/CRRT/ECMO use	No/no/no	No/yes/yes	N/A	Yes/no/no	Yes/No/No	Yes/no/Yes	N/A	Yes/no/no	No/no/No	Yes/no/no
Prognosis	Near normal (3 weeks)	Death after 33 days (healthcare-acquired pneumonia)	N/A	Improvement (on day 6: reduction of LV wall thickness, LVEF 44%, slight decrease of pericardial effusion)	Improved (LVEF 82%) and discharged	Regained biventricular function within few days but required ECMO	Death on arrival	Improvement (normal myocardial injury markers 3 weeks later)	Improved and discharged	Discharged on day 12 completely recovered